Consistent with the hypothesis that PD-L1 is a biomarker of anti-tumour immune response, Taube et al. demonstrated that the survival of patients with PD-L1 positive metastatic melanoma was significantly prolonged. This evidence concerns the gene CD274 and metastatic melanoma.